Skip to main content
Premium Trial:

Request an Annual Quote

Genomas, AutoGenomics Partner to Advance Dx to Personalize Statin Treatments

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics and personalized healthcare company Genomas have signed an agreement to develop genetic tests and DNA-guided diagnostic systems to aid in the selection of statins to improve treatment of heart disease, obesity, and diabetes.

Through this collaboration the companies hope to develop tests and decision support systems together that will help doctors "manage statins, [and] prescribe and dose these drugs on a DNA-guided, personalized basis to more effectively guide the therapy for each patient," the partners said today.

According to the US Centers for Disease Control and Prevention, currently there are 71 million Americans with high levels of low-density lipoprotein (LDL) cholesterol and 43 million are prescribed statins to reduce their LDL. These drugs, however, can cause ill effects in some patients, such as muscle aches, weakness, and cramps, which if gone unmanaged can lead to serious muscle injury.

The tests that Genomas and AutoGenomics plan to advance will identify patients who are likely to experience statin-induced muscle pain or are at risk of experiencing muscle injury. The companies are planning to market Genomas' SINM PhyzioType System for optimizing treatments for lipid disorders on AutoGenomics' Infiniti multiplex genetic testing platform.

"Growing evidence indicates that genetics determines who develops muscle complaints with statins," Paul Thompson, chief of cardiology at the Henry Low Heart Center of Hartford Hospital, said in a statement. "The partnership will allow us to pursue the final implementation studies of the multi-gene biomarker system to personalize cardiovascular therapy."

Genomas is located on the campus of Hartford Hospital, and the company works with the hospital and other institutions to develop its personalized medicine tests.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.